Fluvastatin: A Review of its Pharmacology and Use in the Management of Hypercholesterolaemia

Drugs

Volumn 51, Issue 3, 1996, Pages 433-459

  Plosker, Greg L ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOALGESIA; INSOMNIA; LIVER DYSFUNCTION; MYOPATHY; NAUSEA; ORAL DRUG ADMINISTRATION; REVIEW; RHABDOMYOLYSIS; SINUSITIS; TOOTH DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION;

ANTICHOLESTEREMIC AGENTS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES;

EID: 0029947184     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651030-00011     Document Type: Review

References (131)

1. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994 May 26; 73: 3D-11D
2. Garnett WR. The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor. Clin Cardiol 1994; 17 Suppl. 4: 3-10
3. Fluvastatin sodium. Drugs Future 1991; 16 (9): 804-10
4. Hayashi K, Kurokawa J-i, Nomura S, et al. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim Biophys Acta 1993 Apr 7; 1167: 223-5
5. Parker RA, Clark RW, Sit S-Y, et al. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 1990 Jul; 31: 1271-82
6. Paterniti Jr J. New drugs for inhibiting cholesterol synthesis: experimental studies with fluvastatin. Can J Cardiol 1992 Mar; 8 Suppl. A: 21A-2A
7. Shaw MK, Newton RS, Sliskovic DR, et al. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochem Biophys Res Commun 1990 Jul 31; 170: 726-34
8. Taylor PW. Recent developments in hypolipidaemic investigational drugs. Curr Opin Invest Drug 1993 May; 2: 505-13
9. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors: a new therapeutic approach. Drugs 1988; 36 Suppl. 3: 72-82
10. Moritomo Y, Hirano T, Ebara T, et al. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats. Nephron 1994 Jun; 67: 218-25
11. Shiomi M, Shiraishi M, Yata T, et al. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels: in vivo study using low density lipoprotein receptor deficient Watanabe heritable hyperlipidemic rabbits. Arzneimittel Forschung 1994 Oct; 44: 1154-6
12. Baggio G, De Candia O, Forte PL, et al. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women. Drugs 1944; 47 Suppl. 2: 59-63
13. Banga JD, Jacotot B, Pfister P, et al. Long-term treatment of hypercholesierolemia with fluvastatin: a 52-week multicenter safety and efficacy study. Am J Med 1994 Jun 6; 96: 87S-93S
14. Dallongeville J, Fruchart JC, Pfister P, et al. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). J Intern Med 1994 Dec; 236 Suppl. 736: 95-101
15. Insull JW, Black D, Dujovne C, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994 Nov 14; 154: 2449-55
16. Dallongeville J, Fruchart JC, Pfister P, et al. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group. Am J Med 1994 Jun 6; 96: 32S-6S
17. Anonymous. National cholesterol education program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333-445
18. Betteridge DJ, Durrington PN, Fairhurst GJ, et al. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994 Jun 6; 96: 45S-54S
19. Greten H, Beil FU, Schneider J, et al. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Am J Med 1994 Jun 6; 96 Suppl. 6A: 55S-63S
20. Hagen E, Istad H, Ose L, et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 1994; 46 (5): 445-9
21. Yuan JN, Tsai MY, Hegland J, et al. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991; 87: 147-57
22. de Graaf J, Demacker PNM, Stalenhoef AFH. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med 1993; 43: 254-61
23. Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994; 111: 127-42
24. Corsini A, Raiteri M, Soma M, et al. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991; 23: 173-80
25. Corsini A, Raiteri M, Soma MR, et al. Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem 1992; 25: 399-400
26. Corsini A, Maizotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993 Jun; 101: 117-25
27. Fukuo Y, Nagashima M, Saitoh A, et al. Effects of simvastatin on serum lipids and atherosclerosis in WHHL rabbits. Clin Ther 1991; 13: 417-24
28. Kobayashi M, Ishida F, Takahashi T, et al. Preventative effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn J Pharmacol 1989; 49: 125-33
29. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993 Apr; 13: 571-8
30. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992 Jul; 32: 630-8
31. Smith HT, Jokubaitis LA, Troendle AJ. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993 Nov; 6 (Pt 2) Suppl.: 375S-82S
32. Deslypere J-P. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994 May 26; 73: 12D-7D
33. Masuda N, Akasaka I, Suzuki J, et al. Phase I study of fluvastatin, a new synthetic HMG-CoA reductase inhibitor - pharmacokinetics of fluvastatin in healthy male volunteers after single and multiple oral administration [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 65-81
34. Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994 Jun 6; 96 Suppl. 6A: 37S-40S
35. Tse FLS, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993 Sep; 82: 942-7
36. Guillot F, Misslin P, Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 1993 Feb; 21: 339-46
37. Tse FLS, Labbadia D. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. Biopharm Drug Dispos 1992 May; 13: 285-94
38. Dain JG, Fu E, Gorski J, et al. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993 Jul-Aug; 21: 567-72
39. Expert Report on Clinical Documentation. Application for marketing authorization: expert report on clinical documentation. Sandoz Pharma Ltd., September 18, 1992. (Data on file)
40. Sandoz. Fluvastatin prescribing information. USA
41. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993 Apr; 87 Suppl. 3: III-45-53
42. Sugimoto M, Shibata H. Pharmacokinetics of fluvastatin sodium (XU62-320) in the elderly [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 83-101
43. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202
44. Schucker B, Wittes JT, Santanello NC, et al. Change in cholesterol awareness and action: resuts from national physician and public surveys. Arch Intern Med 1991; 151: 666-73
45. Thelle DS. Epidemiology of hypercholesterolemia and European management guidelines. Cardiology 1990; 77 Suppl. 4: 2-7
46. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. JAMA 1982; 248 (12): 1465-77
47. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317 (20): 1237-45
48. Anonymous. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
49. Anonymous. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
50. Pedersen TR, Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9
51. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: guidelines of the British hyperlipidaemia association. Postgrad Med J 1993; 69: 359-69
52. Peters TK. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database. Am J Cardiol 1995 July 13; 76 (2) Suppl.: 71A-5A
53. Teramoto T, Goto Y, Fluvastatin Study Group in Japan. Clinical efficacy of fluvastatin, a new synthetic HMG-CoA-reductase inhibitor, in long-term treatment of hyperlipidemia: results of a multicenter long-term study. Proceedings of the 10th International Symposium on Atherosclerosis; 1994 Oct 9-14; Montreal, 3a-d.
54. Troendle A. Clinical reviews of fluvastatin: short-term and long-term data. Clin Cardiol 1994; 17 Suppl. 4: IV-11-5
55. Davidson MH, FLUENT Investigation group. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med 1994 Jun 6; 96: 41S-4S
56. Itakura H, Goto Y, Nakamura H, et al. Clinical effect of fluvastatin (XU62-320) on hyperlipidemia - double-blind comparative preliminary dose-finding study in four parallel groups [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 103-29
57. Jacotot B, Banga JD, Pfister P, et al. Efficacy of a low dose-range of fluvastatin (XU-62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. Br J Clin Pharmacol 1994 Sep; 38: 257-63
58. Jacotot B, Banga JD, Waite R, et al. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). Am J Cardiol 1995 July 13; 76 (2) Suppl.: 41A-6A
59. Marcus A. Fluvastatin titrate-to-goal clinical practice study: interim results. Clin Cardiol 1994; 17 Suppl. 4: IV-16-20
60. Saito Y, Goto Y, Yasugi T, et al. Clinical effect of fluvastatin (XU62-320) on hyperlipidemia - double-blind comparative dose-finding study in three parallel groups [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 153-80
61. Teramoto T, Goto Y, Kurokawa K, et al. Clinical efficacy of fluvastatin, a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia-results of a multicenter long-term study [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 235-65
62. Zavoral JH, Haggerty BJ, Winick AG, et al. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. Am J Cardiol 1995 July 13; 76 (2) Suppl.: 37A-40A
63. Peters TK, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a Clinical Trial Database. Am J Hypertens 1993 Nov; 6 (Pt 2) Suppl.: 340-5
64. Peters TK, Muratti EN, Mehra M. Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia. Drugs 1994; 47 Suppl. 2: 64-72
65. Leitersdorf E, Eisenberg S, Eliav O, et al. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia. Eur J Clin Pharmacol 1993; 45 (6): 513-8
66. Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995 July 13; 76 (2) Suppl.: 54A-6A
67. Peters TK, Muratti EN, Mehra M. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database. Am J Med 1994 Jun 6; 96: 79S-83S
68. Abe K, Omata K, Imai Y, et al. Clinical efficacy of fluvastatin (XU62-320) on hyperlipidemia in essential hypertensives [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 109-31
69. Matsumoto M, Handa N, Hougaku H, et al. Clinical evaluation of XU62-320 (fluvastatin sodium) in treatment of hyperlipidemia with essential hypertension [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 133-52
70. Toyama J, Yamada K, Kobayashi T, et al. Clinical effect of fluvastatin (XU62-320) in hyperlipidemia with essential hypertension [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 153-70
71. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994 Jun 6; 96 Suppl. 6A: 64S-8S
72. Leitersdorf E. Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia. Drugs 1994; 47 Suppl. 2: 54-8
73. Hashimoto T, Nakatani A, Dohi K. Clinical effects of XU62-320 (fluvastatin) on hyperlipidemia in elderly patients [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 29-44
74. Morimoto S, Nakahashi T, Fukuo K, et al. Clinical efficacy of XU62-320 (fluvastatin) in elderly patients with hyperlipidemia [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 3-28
75. Leitersdorf E, Eisenberg S, Eliav O, et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993 Apr; 87 Suppl. 3: III-35-44
76. Knopp RH, Frohlich J, Jokubaitis LA, et al. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994 Jun 6; 96 Suppl. 6A: 69S-78S
77. Goldberg RB, Roth D. Fluvastatin safety, efficacy and kinetics in the treatment of hypercholesterolemia in renal-transplant patients receiving cyclosporine. Proceedings of the 10th International Symposium on Atherosclerosis; 1994 Oct 9-14; Montreal, 6a-d.
78. Foley DP, Bonnier H, Jackson G, et al. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restonosis (FLARE) Trial. Am J Cardiol 1994 May 26; 73: 50D-61D
79. Herd JA, West MS, Ballantyne C, et al. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol 1994 May 26; 73: 42D-9D
80. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16 (3): 366-85
81. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther 1996; 1 (1): 23-30
82. Ose L, Scott R, Simvastatin-Fluvastatin Study Group. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clinical Drug Investigation 1995; 10 (3): 127-38
83. Pfister P, Mehra M, Wigart C. Study XUC 116-E-00/01 clinical report. Sandoz Pharma Ltd., 1992. Study XUC 116-E-00/01 clinical report. (Data on file)
84. Pfister P, Mehra M, Wigart C. Study XUC 116-E-00/01 clinical report. Sandoz Pharma Ltd., 1992. Study XUC 116-E-00/01 clinical report. (Data on file)
85. Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994 Jun 18; 343: 1554-5
86. Jacobson TA. Combination drug therapy for hyperlipidemia. Clin Cardiol 1994; 17 Suppl. 4:IV-28-34
87. Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994 Jul 15; 74: 149-54
88. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Med 1994 May; 96: 401-7
89. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994 Apr 1; 120: 537-43
90. Miyake S, Izumi N, Obayashi T. Combination therapy with a new HMG-CoA reductase inhibitor fluvastatin and cholestyramine in treatment of hypercholesterolemia [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 307-19
91. Muratti EN, Peters TK, Leitersdorf E. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment. Am J Cardiol 1994 May 26; 73: 30D-8D
92. Ageta M, Matsuo T, Kumagai H. Combined therapy of fluvastatin, a new HMG-CoA reductase inhibitor, and bezafibrate in hyperlipidemic patients with type IIb [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 191-209
93. Eliav O, Schurr D, Pfister P, et al. High-dose fluvastatin + bezafibrate combination treatment of patients with heterozygous familial hypercholesterolemia. Proceedings of the 10th International Symposium on Atherosclerosis; 1994 Oct 9-14; Montreal, 11a-b.
94. Sasaki S, Nakagawa M, Nakata T, et al. The efficacy and safety of HMG-CoA reductase inhibitor, XU62-320 (fluvastatin sodium), in hyperlipidemic patients treated with probucol [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 211-29
95. Sprecher DL, Jokubaitis L. Cost-effectiveness of combined statin-resin therapy. Reply [letter]. Ann Intern Med 1994 Oct 1; 121: 548-9
96. New cholesterol-lowering program focuses on lowering cost per patient treated [editorial]. Hosp Formul 1994; 29: 802
97. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16: 1052-62
98. Hogan T. Health and economic issues in the prevention of coronary artery disease. Am J Cardiol 1995 July 13; 76 (2) Suppl.: 140A-2A
99. Chrisp P, Lewis NJW, Milne RJ. Simvastatin. A pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992; 1 (2): 124-45
100. Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolaemia. A review of the literature. PharmacoEconomics 1992; 2 (1): 34-42
101. Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol 1994 May 26; 73: 18D-24D
102. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 131: 43-9
103. McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther 1993; 15 (1): 57-64
104. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995; 50 (2): 334-363
105. Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors [letter]. JAMA 1990 Dec 19; 264: 2992
106. Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992; 70: 1-9
107. Tobert JA. Efficacy and long term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62 (11): 28J-34J
108. Yamamoto T, Abe E, Kawahara J, et al. Clinical safety and tolerability of long-term treatment with fluvastatin (XU62-320) in hypercholesterolemia - ophthalmological effect [in Japanese]. Rinsho Iyaku 1995; 11 (3): 651-71
109. Boccuzzi ST, Bocanegra TS, Walker JF. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-31
110. Laties AM, Shear CL, Lippa EA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol 1991; 67: 447-53
111. Drury JH, Cohen JD. Medical management of the high-risk dyslipidemic patient - the role of fluvastatin, the newest HMG-CoA reductase inhibitor. Today's Therapeutic Trends, In press
112. Ito H, Nakano T, Yoshida S, et al. The effects of the long-term treatment of fluvastatin, a newly developed HMG-CoA reductase inhibitor, on serum lipid and endocrine function in hyperlipidemic subjects [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 2: 45-78
113. Smit JWA, Janssen GH, Erkelens DW. Fluvastatin and gemfibrozil alone and in combination do not induce muscle damage in combined hyperlipidemia. Proceedings of the 10th International Symposium on Atherosclerosis; 1994 Oct 9-14; Montreal, 9a-b.
114. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol 1994 May 26; 73: 25D-9D
115. Holdaas H, Hartmann A, Stenstrom J, et al. Fluvastatin lowers atherogenic lipids safely in renal-transplant patients taking cyclosporine. Proceedings of the 10th International Symposium on Atherosclerosis; 1994 Oct 9-14; Montreal, 5a-d.
116. Li PKT, Mak TWL, Wang AYM, et al. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther 1995; 33 (4): 246-8
117. Arnadottir M, Eriksson L-O, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-3
118. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 Suppl. 4: IV-281-3
119. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993 Aug; 25 (4): 2732-4
120. Peters TK, Jewitt-Harris J, Mehra M. Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a Clinical Trial Database. Am J Hypertens 1993 Nov; 6 (Pt 2) Suppl.: 346S-52S
121. Transon C, Leemann T, Dayer P. Selective in vitro P450 inhibition profile by fluvastatin indicates its potential in vivo drug interactions [abstract]. Clin Pharmacol Ther 1993 Feb; 53: 188
122. Ahmad S. Lovastatin warfarin interaction. Arch Intern Med 1990; 150: 2407
123. Walker JF. Simvastatin: the clinical profile. Am J Med 1989 October 16; 87 Suppl. 4A: 44S-6S
124. Appel S, Rüfenacht T, Kalafsky G, et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995 July 13; 76 (2) Suppl.: 29A-32A
125. Garnett WR, Venitz J, Wilkens RC, et al. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994 Jun 6; 96 Suppl. 6A: 84S-6S
126. Smit JW, Wijnne HG, Schobben F, et al. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function. Ann Intern Med 1995; 122 (9): 678-80
127. Nakaya N, Goto Y, Inoue T. Clinical effect of fluvastatin (XU62-320) on hyperlipidemia - dose frequency study in a double-blind comparative method [in Japanese]. Rinsho Iyaku 1995; 11 Suppl. 1: 131-51
128. Conti CR. Economics of lipid lowering with HMG CoA reductase inhibitors [editorial]. Clin Cardiol 1995; 18: 60
129. US National Center for Health Services C for DC and P. National health and nutrition examination survey III (NHANES III). (Data on file)
130. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholeslerolaemia. N Engl J Med 1995; 333 (20): 1301-7
131. Haasis R, Berger J. Fluvastatin versus lovastatin - eine randomisierte, doppelblinde, multizentrische parallel-gruppenstudie zur effektivität und sicherheit einer lipidsenkung. Herz Kreisl 1995; 27 (11): 375-80